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Currently, much effort is invested into 
the development of non-animal testing strat-
egies to identify the potential of compounds 
to induce systemic toxicity (Hammad, 2013; 
Stewart and Marchan, 2012). Organotypical 
in vitro systems are particularly popular in 
the fields of kidney (Limonciel et al., 2012; 
Jennings et al., 2012; Valente et al., 2012), 
heart (Maayah et al., 2014; Bonifacio et al., 
2014), liver (Grinberg et al., 2014; Godoy et 
al., 2013; Schug et al., 2013) and develop-
mental toxicity (Weng et al., 2014; Wald-
mann et al., 2014; Krug et al., 2013). How-
ever, it is also clear that in vitro systems rep-
resent valuable tools to study certain mecha-
nisms and endpoints but do not reach the 
complexity of organs or organisms (Ghallab, 
2013).  
Recently, Daston et al. (2014) published 
a concept, how future research on non-
animal methodology should be designed to 
overcome current limitations. The authors 
recommend two complementary and inter-
connecting concepts. A first work stream 
should focus on toxicity characterization. 
Here, critical biological targets and mecha-
nisms leading to toxic effects should be elu-
cidated based on in vitro systems. For this 
purpose methods such as high-throughput 
and high content screening and computation-
al modelling will be applied (Daston et al., 
2014). A second work stream should focus 
on translation into regulation. Specific aims 
are for example methods for grouping, read-
across strategies and in vitro methods to de-
rive no-effect levels. In recent years much 
has been written about grouping strategies 
and general concepts to improve chemical 
risk evaluation (Geenen et al., 2012; Kalkhof 
et al., 2012; Keller et al., 2009; Renwick, 
2004; Zbinden, 1993; Gebel et al., 2014; 
Calabrese, 2013). The present concept paper 
of Daston and colleagues (2014) belongs cer-
tainly to the most fundamental papers in this 
field and is a must-read for anyone interested 
in predictive toxicology and alternative 
methods. However, the authors neglect one 
major limitation of their strategy: The con-
cept may lead to reasonable predictions for 
chemicals with unspecific mechanisms of 
action, meaning that many mechanisms are 
simultaneously active that lead to the break-
down of cellular functions. However, the 
concept may fail for highly specific mecha-
nisms of action. The reason for this limita-
tion is that Daston et al. (2014) in agreement 
with the SEURAT concept recommend fo-
cusing on ‘critical biological targets’ in in 
vitro systems only (Jennings et al., 2014). 
This bears the risk of establishing an illusory 
in vitro world which lacks critical compo-
nents of real organs or organisms. Let us as-
sume a compound specifically inhibits reab-
sorption of bile salts in cholangiocytes in 
bile ducts. How should this mechanism be 
recognized in an in vitro system that contains 
hepatocytes only? Moreover, it cannot be 
excluded that a compound may alter kidney 
cells in a way that triggers the attack of im-
mue cells. Can we be sure that this specific 
mechanism would be identified in an in vitro 
system containing renal proximal tubular ep-
ithelial cells only? A research program to in 
vitro systems only has a high probability to 
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fail. Therefore, a third work stream is pain-
fully missing in the concept of Daston et al. 
(2014); namely research that systematically 
compares mechanisms of toxicity in vitro 
and in vivo. Do the currently available in 
vitro systems really recapitulate the mecha-
nisms that finally lead to adverse effects in 
vivo? Finally, it should not be ignored that 
many mechanisms leading to toxicity in vivo 
are far from being fully understood. Further 
research is needed to identify key mecha-
nisms of toxicity in vivo to be able to estab-
lish in vitro systems recapitulating these 
mechanisms. Although it may seem paradox: 
the successful development of non-animal 
methodology requires animal experiments.  
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